Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171751 | 1.00 | THRA (0.70) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL4785017 | 0.99 | THRA (0.68) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL27669784 | 0.96 | THRA (0.65) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL3171378 | 0.92 | THRA (0.61) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL2593666 | 0.92 | THRA (0.59) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL2957056 | 0.90 | THRA (0.69) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL27754609 | 0.89 | THRA (0.74) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL25789823 | 0.89 | PLA2G2D (0.65) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL9307228 | 0.87 | THRA (0.70) | THRATHRBPLA2G2DALDH1A1HPGD | |
| SCHEMBL9307582 | 0.87 | THRA (0.70) | THRATHRBPLA2G2DALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3819285-B1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-06-08 | — | — | EP | disclosed |
| EP-3819285-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| EP-3492448-B1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-10752575-B2 | 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3492448-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-20190161432-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-05-30 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-1961734-B1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1961734-B1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | THRA 705/4885THRB 536/4885PLA2G2D 3558/4885 |
| US-20190161432-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | ADH1C, ADH5, ADH1A | THRA 2107/4885THRB 1031/4885PLA2G2D 3877/4885 |
| US-10752575-B2 | 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method | ADH1C, ADH5, ADH1A | THRA 2107/4885THRB 1031/4885PLA2G2D 3877/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | THRA 705/4885THRB 536/4885PLA2G2D 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.